MiniMed Accelerates U.S. Growth, Raises FY27 Guidance
Event summary
- MiniMed reported $843M in Q1 FY27 net sales, up 17% YoY (16% organic), with U.S. growth accelerating to 13% YoY.
- International sales grew 18% YoY (17% organic), driven by Simplera™ capacity expansion and Instinct sensor launches.
- MiniMed Fit™ patch pump submitted to FDA ahead of schedule, with full U.S. launch expected Summer 2027.
- Raised FY27 organic revenue growth guidance to 10.5% from 10%, including 1-1.5% benefit from extra week in Q1.
- Worldwide CGM attachment rate increased to 69%, up ~100 bps quarter over quarter.
The big picture
MiniMed's strong Q1 FY27 performance highlights its ability to accelerate U.S. growth while maintaining robust international expansion. The company's strategic focus on an integrated ecosystem of insulin delivery systems, CGMs, and algorithms positions it to strengthen its leadership in automated insulin delivery. The upcoming launches of MiniMed Fit™ and next-gen sensors will be critical in sustaining this momentum amid competitive pressures in the diabetes technology market.
What we're watching
- Pipeline Execution
- Whether MiniMed can sustain its ahead-of-schedule product launches, including the MiniMed Fit™ patch pump and next-gen extended wear sensor.
- U.S. Market Penetration
- How the expansion of MiniMed Flex™ coverage to Medicare and Medicare Advantage beneficiaries will impact new patient acquisition and competitive conversions.
- International Growth
- The pace at which MiniMed can scale its international business, particularly in Europe with the launch of the MiniMed™ 780G system and Instinct sensor.